Literature DB >> 24641481

Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization.

David A Sykes1, Darren M Riddy, Craig Stamp, Michelle E Bradley, Neil McGuiness, Afrah Sattikar, Danilo Guerini, Ines Rodrigues, Albrecht Glaenzel, Mark R Dowling, Florian Mullershausen, Steven J Charlton.   

Abstract

BACKGROUND AND
PURPOSE: The molecular mechanism underlying the clinical efficacy of FTY720-P is thought to involve persistent internalization and enhanced degradation of the S1P1 receptor subtype (S1P1R). We have investigated whether receptor binding kinetics and β-arrestin recruitment could play a role in the persistent internalization of the S1P1R by FTY720-P. EXPERIMENTAL APPROACH: [(3) H]-FTY720-P and [(33) P]-S1P were used to label CHO-S1P1/3Rs for binding studies. Ligand efficacy was assessed through [(35) S]-GTPγS binding and β-arrestin recruitment. Metabolic stability was evaluated using a bioassay measuring intracellular Ca(2+) release. CHO-S1P1/3R numbers were determined, following FTY720-P treatment using flow cytometry. KEY
RESULTS: The kinetic off-rate of [(3) H]-FTY720-P from the S1P1R was sixfold slower than from the S1P3R, and comparable to [(33) P]-S1P dissociation from S1P1/3Rs. S1P and FTY720-P stimulated [(35) S]-GTPγS incorporation to similar degrees, but FTY720-P was over 30-fold less potent at S1P3Rs. FTY720-P stimulated a higher level of β-arrestin recruitment at S1P1Rs, 132% of the total recruited by S1P. In contrast, FTY720-P was a weak partial agonist at S1P3R, stimulating just 29% of the total β-arrestin recruited by S1P. Internalization experiments confirmed that cell surface expression of the S1P1R but not the S1P3R was reduced following a pulse exposure to FTY720-P, which is metabolically stable unlike S1P. CONCLUSIONS AND IMPLICATIONS: FTY720-P and S1P activation of the S1P1R results in receptor internalization as a consequence of an efficient recruitment of β-arrestin. The combination of slow off-rate, efficacious β-arrestin recruitment and metabolic stability all contribute to FTY720-P's ability to promote prolonged S1P1R internalization and may be critical factors in its efficacy in the clinic.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24641481      PMCID: PMC4294105          DOI: 10.1111/bph.12620

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.

Authors:  Kenneth LaMontagne; Amanda Littlewood-Evans; Christian Schnell; Terence O'Reilly; Lorenza Wyder; Teresa Sanchez; Beatrice Probst; Jeannene Butler; Alexander Wood; Gene Liau; Eric Billy; Andreas Theuer; Timothy Hla; Jeanette Wood
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate.

Authors:  Euijung Jo; M Germana Sanna; Pedro J Gonzalez-Cabrera; Shobha Thangada; Gabor Tigyi; Daniel A Osborne; Timothy Hla; Abby L Parrill; Hugh Rosen
Journal:  Chem Biol       Date:  2005-06

3.  The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity.

Authors:  Padmavathi Bandhuvula; Yuen Yee Tam; Babak Oskouian; Julie D Saba
Journal:  J Biol Chem       Date:  2005-08-23       Impact factor: 5.157

4.  Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.

Authors:  Myat Lin Oo; Shobha Thangada; Ming-Tao Wu; Catherine H Liu; Timothy L Macdonald; Kevin R Lynch; Chen-Yong Lin; Timothy Hla
Journal:  J Biol Chem       Date:  2007-01-21       Impact factor: 5.157

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses.

Authors:  Sindy H Wei; Hugh Rosen; Melanie P Matheu; M Germana Sanna; Sheng-Kai Wang; Euijung Jo; Chi-Huey Wong; Ian Parker; Michael D Cahalan
Journal:  Nat Immunol       Date:  2005-11-06       Impact factor: 25.606

Review 7.  Sphingosine-1-phosphate: an enigmatic signalling lipid.

Authors:  Sarah Spiegel; Sheldon Milstien
Journal:  Nat Rev Mol Cell Biol       Date:  2003-05       Impact factor: 94.444

8.  Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity.

Authors:  V V Gurevich; R Pals-Rylaarsdam; J L Benovic; M M Hosey; J J Onorato
Journal:  J Biol Chem       Date:  1997-11-14       Impact factor: 5.157

Review 9.  Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.

Authors:  Kenji Chiba; Hirofumi Matsuyuki; Yasuhiro Maeda; Kunio Sugahara
Journal:  Cell Mol Immunol       Date:  2006-02       Impact factor: 11.530

10.  Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis.

Authors:  Hervé Le Stunff; Aki Mikami; Paola Giussani; John P Hobson; Puneet S Jolly; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2004-06-04       Impact factor: 5.157

View more
  20 in total

1.  Endocytosis of Ligand-Activated Sphingosine 1-Phosphate Receptor 1 Mediated by the Clathrin-Pathway.

Authors:  Patrick M Reeves; Yuan-Lin Kang; Tom Kirchhausen
Journal:  Traffic       Date:  2015-12-09       Impact factor: 6.215

Review 2.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

Review 3.  S1P Signaling and De Novo Biosynthesis in Blood Pressure Homeostasis.

Authors:  Anna Cantalupo; Annarita Di Lorenzo
Journal:  J Pharmacol Exp Ther       Date:  2016-06-17       Impact factor: 4.030

Review 4.  Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases.

Authors:  Nathalie Burg; Jane E Salmon; Timothy Hla
Journal:  Nat Rev Rheumatol       Date:  2022-05-04       Impact factor: 20.543

5.  Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism.

Authors:  Zhenmei Xu; Tatsuya Ikuta; Kouki Kawakami; Ryoji Kise; Yu Qian; Ruixue Xia; Ming-Xia Sun; Anqi Zhang; Changyou Guo; Xue-Hui Cai; Zhiwei Huang; Asuka Inoue; Yuanzheng He
Journal:  Nat Chem Biol       Date:  2021-12-22       Impact factor: 16.174

6.  Fingolimod Phosphate (FTY720-P) Activates Protein Phosphatase 2A in Human Monocytes and Inhibits Monosodium Urate Crystal-Induced Interleukin-1β Production.

Authors:  Marwa Qadri; Sandy ElSayed; Khaled A Elsaid
Journal:  J Pharmacol Exp Ther       Date:  2020-11-25       Impact factor: 4.030

7.  Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3.

Authors:  Chao Li; Jun-nan Li; Joanne Kays; Miguel Guerrero; Grant D Nicol
Journal:  J Neuroinflammation       Date:  2015-04-12       Impact factor: 8.322

8.  The role of kinetic context in apparent biased agonism at GPCRs.

Authors:  Carmen Klein Herenbrink; David A Sykes; Prashant Donthamsetti; Meritxell Canals; Thomas Coudrat; Jeremy Shonberg; Peter J Scammells; Ben Capuano; Patrick M Sexton; Steven J Charlton; Jonathan A Javitch; Arthur Christopoulos; J Robert Lane
Journal:  Nat Commun       Date:  2016-02-24       Impact factor: 14.919

Review 9.  Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential.

Authors:  Masayo Aoki; Hiroaki Aoki; Rajesh Ramanathan; Nitai C Hait; Kazuaki Takabe
Journal:  Mediators Inflamm       Date:  2016-02-07       Impact factor: 4.711

10.  GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats.

Authors:  Wijnand J C van der Velden; Florent X Smit; Charlotte B Christiansen; Thor C Møller; Gertrud M Hjortø; Olav Larsen; Sine P Schiellerup; Hans Bräuner-Osborne; Jens J Holst; Bolette Hartmann; Thomas M Frimurer; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.